Spontaneous Remission and Subsequent Relapse in Pediatric Acute Myeloid Leukemia (AML-M5): A Case Report and Literature Review.

Eur J HaematolOct 29, 2025 (epub)
Case ReportHematologyPediatricsOncology (Medical)Open access

Li Rongjie, Qiu Lijuan, Zhou Bailing et al.

✦ AI-curated · Sources linked

Case in brief

A child with acute myeloid leukemia, French-American-British subtype M5 (AML-M5), experienced spontaneous remission after receiving blood transfusions and anti-infective therapy, without leukemia-specific treatment. The leukemia relapsed one month later. The report also reviewed literature on factors associated with spontaneous remission in pediatric leukemia.

What made this case unusual

The remission occurred without leukemia-specific treatment after supportive transfusions and anti-infective therapy, but was followed by relapse within one month.

Diagnostic / clinical pearl

A spontaneous remission in pediatric AML-M5 does not establish durable disease control; this case relapsed one month later.

Source

PubMed · PMID 41159499Free full text on PubMed Central

Published in Eur J Haematol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.